Collegium Pharmaceutical Inc (COLL) - News Archive

Showing 6 of 6 results.

Collegium Pharmaceuticals Expands Neurology Footprint with the Launch of Jornay PM,

Collegium Pharmaceuticals Expands Neurology Portfolio with Launch of Jornay PMCollegium Pharmaceutical Inc. (NASDAQ: COLL), a notable player in the pharmaceutical preparation industry, is making substantial strides in e...

Sep 4, 2024 • Major Pharmaceutical Preparations Industry Merger and Acquisition

Collegium Expands Neurological Portfolio with Jornay PM Acquisition, Setting Course for Future Innovations

In a compelling strategic move, Collegium Pharmaceutical Inc. (NASDAQ: COLL) has announced the addition of its commercial product, Jornay PM, a formulation designed specifically to aid individuals with Attention-Deficit...

Jul 29, 2024 • Major Pharmaceutical Preparations Industry Merger and Acquisition

On June 13, 2024, Collegium Pharmaceutical, Inc. (Nasdaq COLL), a renowned specialty pharmaceuti...

Extension of Pediatric Exclusivity for Nucynta® Franchise: Implications and Future Directions On June 13, 2024, Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a renowned specialty pharmaceutical company, proudly announc...

Jun 13, 2024 • Major Pharmaceutical Preparations Industry Product Service News

Collegium Pharmaceutical, Inc, a leading specialty pharmaceutical company focused on improving the lives of individuals with serious medical conditions, has recently announced a significant step towards enhancing shareholder value The company has entered into an Accelerated Share Repurchase (ASR) agreement with Jefferies LLC, with plans to repurchase $35 million of its common stock This ASR is part of Collegium's previously authorized $150 million share repurchase program, approved by its Board of Directors in January 2024

Collegium Pharmaceutical, Inc., a leading specialty pharmaceutical company focused on improving the lives of individuals with serious medical conditions, has recently announced a significant step towards enhancing share...

May 13, 2024 • Major Pharmaceutical Preparations Industry Stock Market Announcement

Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta and Nucynta ER: Assessing the Impact on the Company

In a recent announcement, Collegium Pharmaceutical, Inc. revealed a significant step forward in its efforts to improve the lives of individuals dealing with serious medical conditions. The company has entered into an au...

Apr 29, 2024 • Major Pharmaceutical Preparations Industry Contract

Collegium Pharmaceutical Announces $25 Million Accelerated Share Repurchase Program to Maximize Shareholder Value

Collegium Announces $25 Million Accelerated Share Repurchase ProgramCollegium Pharmaceutical, Inc., a renowned specialty pharmaceutical company dedicated to enhancing the lives of individuals grappling with severe medic...

Nov 9, 2023 Contract